SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY ARTICLE M impact

SAB Biotherapeutics to Host Q3 2026 Results Call November 5

SAB Biotherapeutics said it will host its third-quarter 2026 financial results conference call and webcast on November 5, 2026, at 8:30 a.m. ET.

SABS
SquawkNews Desk

MIAMI, Oct. 29, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced that its third quarter 2026 financial…

Related stories

Nasdaq pauses volatility trading Nasdaq announced a volatility trading pause at 11:22 a.m. L impact | EQUITY | Oct 29, 2026, 03:27 PM UTC DFM Reports Quarterly Net Profit of 130.5 Million Dirhams M impact | EQUITY | Oct 29, 2026, 03:21 PM UTC Oshkosh Reports Third-Quarter Revenue of $2.84 Billion Oshkosh reported third-quarter 2026 revenue of $2.84 billion, up 5.7% year over year. Net income fell 29.5% to $138.4 million and diluted EPS declined 27% to $2.22. M impact | EQUITY | Oct 29, 2026, 03:21 PM UTC Pitney Bowes Reports Quarterly Revenue of $456.18 Million, Net Income of $52.67 Million Pitney Bowes reported quarterly revenue of $456.18 million and net income of $52.67 million, compared with $459.68 million and $51.96 million a year earlier. Diluted EPS was $0.37, M impact | EQUITY | Oct 29, 2026, 03:21 PM UTC Bristol Myers Squibb Reports Q3 2026 Revenue of $13.07B, EPS of $1.05 Revenue rose 6.9% year over year to $13.07 billion. Net income fell 1.5% to $2.16 billion, while diluted EPS declined 2.8% to $1.05. M impact | EQUITY | Oct 29, 2026, 03:21 PM UTC DFM quarterly net profit attributable at 130.5 million dirhams M impact | EQUITY | Oct 29, 2026, 03:21 PM UTC